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a,b,c LebanonBackground: The use of the Coronary Artery Calcium Score (CACS) for risk categorization instead of the
Framingham Risk Score (FRS) or European Heart SCORE (EHS) to improve classification of individuals is well
documented. However, the impact of reclassifying individuals using CACS on initiating lipid lowering therapy is not
well understood. We aimed to determine the percentage of individuals not requiring lipid lowering therapy as per the
FRS and EHS models but are found to require it using CACS and vice versa; and to determine the level of agreement
between CACS, FRS and EHS based models.
Methods: Data was collected for 500 consecutive patients who had already undergone CACS. However, only 242
patients met the inclusion criteria and were included in the analysis. Risk stratification comparisons were conducted
according to CACS, FRS, and EHS, and the agreement (Kappa) between them was calculated.
Results: In accordance with the models, 79.7% to 81.5% of high-risk individuals were down-classified by CACS,
while 6.8% to 7.6% of individuals at intermediate risk were up-classified to high risk by CACS, with slight to mod-
erate agreement. Moreover, CACS recommended treatment to 5.7% and 5.8% of subjects untreated according to
European and Canadian guidelines, respectively; whereas 75.2% to 81.2% of those treated in line with the guidelines
would not be treated based on CACS.
Conclusion: In this simulation, using CACS for risk categorization warrants lipid lowering treatment for 5–6%
and spares 70–80% from treatment in accordance with the guidelines. Current strong evidence from double
FU
LL
 L
EN
G
TH
 A
RT
IC
LE
J Saudi Heart Assoc
2015;27:234–243
ISMA’EEL ET AL 235
QUANTIFYING THE IMPACT OF USING CORONARY ARTERY
CALCIUM SCORE FOR RISK CATEGORIZATION INSTEAD OF FRAMINGHAM SCORE OR EUROPEAN
HEART SCORE IN LIPID LOWERING ALGORITHMS IN A MIDDLE EASTERN POPULATIONrandomized clinical trials is in support of guideline recommendations. Our results call for a prospective trial to
explore the benefits/risks of a CACS-based approach before any recommendations can be made.
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AU Agatston units
CACS Coronary Artery Calcium Score
CCS Canadian Cardiology Society
CHD Coronary Heart Disease
CV Cardiovascular
EHS European Heart SCORE
ESC European Society of Cardiology
FRS Framingham Risk Score
NRI Net Reclassification IndexIntroduction
The Coronary Artery Calcium Score (CACS),measured in Agatston units (AU), is a non-
invasive method of measuring calcification in the
coronary arteries [1]. It is used to assess the overall
coronary calcified plaque burden thereby provid-
ing prognostic information regarding the occur-
rence of future cardiovascular (CV) events [2,3].
A high CACS indicates that individuals are at high
risk for cardiovascular events even if they were
classified as having low or intermediate risk using
traditional risk assessment tools such as the
Framingham risk score (FRS), as adopted by
the Canadian Cardiology Society (CCS) [4], or
the European Heart SCORE (EHS) [5]. These
individuals may necessitate aggressive preventive
lipid lowering therapy [6].
Historically, incorporating the traditional CV
risk factors such as blood pressure, age, gender,
smoking, and cholesterol levels into the FRS and
EHS models aided clinicians in risk classification
and in decisions on initiating therapeutics [5].
However, experience – supported by various
studies – has demonstrated the shortcomings of
these models in predicting coronary heart disease
(CHD) [7,8]. CACS has become a well-established
surrogate marker of coronary atherosclerosis [9].
Despite the fact that the mechanism underlying
CAC deposition within atherosclerotic plaque is
not yet entirely clear, CAC has been shown in
autopsy studies to significantly correlate with the
overall coronary tree plaque burden [10].
Improvement in CHD risk prediction using
CACS in comparison to traditional risk factors is
well documented. Five major studies have signifi-
cantly and favorably influenced the opinions of
scientific communities on the usefulness of
CACS as a predictor of events. These are the
Multi-Ethnic Study of Atherosclerosis (MESA)
[11], the Heinz Nixdorf Recall (HNR) study [12],
the Rotterdam study [13], the JUPITER-MESA
study [14], and the publications from the
CONFIRM Registry [15]. These studies showed
that CACS is an independent predictor for CHD[16] and has added value over the FRS tool in that
it performs similarly in multiple ethnicities and
works well in both women and men. Currently,
the AHA categorizes CAC scoring as a Class 2B
recommendation among asymptomatic persons
at intermediate risk for cardiac events by the
FRS tool [17].
The clinical utilization of CACS has been vali-
dated in several areas, with varying levels of evi-
dence in the area of reclassifying an individual’s
risk for CHD events and in improving adherence
with preventive therapeutic recommendations.
Recent evidence suggests that reclassification
of patients from intermediate risk as per
Framingham risk score to high-risk status based
on CACS warrants aggressive preventive therapy,
especially as treatment decisions for this group
are indecisive [2]. However, no evidence-based
guidelines currently exist on how to implement
CACS risk categorization in treatment algorithms.
The utilization of CACS for risk stratification is
gaining wide acceptance [18], and appears to
impact both the patient at the individual level
and the healthcare system at large. Whereas the
net reclassification index is the most consulted
measure in the literature, the initiation of thera-
peutics amongst all up-classified individuals
remains a current practice. This may be justified
since there is no proof that intensive preventive
interventions can be safely reduced in persons at
high Framingham risk and low risk by CACS
[13]. Hence, quantifying the impact of up and
down-classification on initiating therapeutics will
enable improved clarification of the cost–benefits
to CACS utilization [19].
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percentage of individuals not requiring lipid-
lowering therapy as per FRS and EHS models but
who are found to require lipid-lowering interven-
tions using CACS, and to quantify the opposite sce-
nario. Second, we aim to determine the level of
agreement between the CACS method of CV risk
classification and the FRS and EHS models.Methods
This is a cross-sectional study within a nested
cohort of patients who have already undergone
CAC scoring. The cohort was identified through
an interrogation of the Imaging Storage Digital
system. A retrospective chart review for 500 con-
secutive patients included collection of data on
patients’ medical history of co-morbidities includ-
ing diabetes, hypertension, dyslipidemia, and
family history of CAD and cardiovascular event
occurrence. Data collected also included medica-
tions received, blood test results including lipid
profile and fasting blood sugar, heart rate and
blood pressure measurement, and lifestyle habits
including smoking. This study was approved by
the institutional review board at the American
University of Beirut. A total of 242 patients eligible
for the study were included in the analysis.
Exclusion criteria included patients with type 2
diabetes mellitus (DM), aged 40 years or less,
already on statin treatment or other lipid lowering
therapy, having a history of coronary artery
bypass grafting before the CT scan, having signif-
icant stenosis (defined as more or equal to 50%
stenosis by the CT coronary angiography) or hav-
ing undergone percutaneous coronary interven-
tion (balloon dilatation or stent deployment) in
one of the coronary arteries. These patients were
excluded as they were already categorized as high
risk and CAC scoring for the purpose of lipid low-
ering is not warranted. As for type 2 diabetic
patients, they were excluded because recommen-
dations to initiate lipid lowering are different from
the general population in being not dependent on
FRS or EHS models. In brief, the group we chose
to include is dependent on FRS or EHS models
for determining subsequent lipid therapy.Definitions of terms used
Family history of CAD was defined as any direct
blood relatives (parents, siblings, or children) who
have had acute myocardial infarction or sudden
cardiac death without obvious cause, coronary
artery bypass graft surgery, or percutaneous coro-
nary intervention at an age less than 55 years formale relatives or less than 65 years for female
relatives [20,21].
Hypertension was defined by three criteria,
where having either one would make the subject
a positive case. The criteria included having a his-
tory of hypertension diagnosed and treated with
medication, diet and/or exercise. The second was
prior documentation of blood pressure greater
than 140 mm Hg systolic and/or 90 mm Hg dias-
tolic for patients without diabetes or chronic kid-
ney disease. The third was prior documentation
of blood pressure greater than 130 mm Hg systolic
and/or 80 mm Hg diastolic on at least two occa-
sions for patients with diabetes or chronic kidney
disease [22].
Type 2 diabetes mellitus was defined as any
occurrence of Hemoglobin A1c (HbA1C) P6.5 or
Fasting blood sugar (FBS) P126 mg/dL in labora-
tory tests or documentation of DM 2 by the treat-
ing physician. Current or recent smoking indicates
if the patient had smoked cigarettes anytime dur-
ing the month prior to arrival at our facility.
Identifying a positive dyslipidemia case was
based on the National Cholesterol Education
Program criteria and included documentation
of a total cholesterol greater than 200 mg/dL
(5.18 mmol/l), low-density lipoprotein (LDL) greater
than or equal to 130 mg/dL (3.37 mmol/l); high-
density lipoprotein (HDL) less than 40 mg/dL
(1.04 mmol/l) [23]. Moreover, patients on treat-
ment for hypercholesterolemia with statins or
Ezetimibe were considered to have dyslipidemia.Risk classification of patients
The CCS Guidelines categorize patients into low
(FRS <10%), intermediate (10% < FRS <20%), and
a high (FRS >20%) 10-year risk of developing car-
diovascular (CV) disease [20,24].
Similarly, using EHS, the 10-year risk for CV
death was calculated. Thereafter, patients were
classified into low (<1%), intermediate (1–5%),
and high (>5%) 10-year risk for CV death, and
based on the European Society of Cardiology
(ESC) guidelines, the downstream treatment indi-
cations were determined [25].
Finally, using CACS, patients were categorized
into low (<100 AU), intermediate (100–399 AU)
and high (>400 AU) 10-year CV event rate [26].
Subsequently, this risk categorization was
inserted instead of the risk categorization by the
FRS and EHS in their corresponding algorithms,
and thereafter downstream treatment indications
were derived.
The use of these cut-points is based on the
American College of Cardiology/American Heart
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sensus document on coronary artery calcium scor-
ing. It was found that the estimated annual risk of
CHD death or myocardial infarction (MI) rates to
be ‘‘0.4%, 1.3%, and 2.4% for each tertile of CAC
score where scores ranged from less than 100,
100 to 399, and greater than or equal to 400,
respectively’’ [27]. A simplified approach would
permit the assumption that when projected for
10-year rates, 4% is below the 10% cutoff for 10-
year risk, that is, low risk; 13% is below the 20%
cutoff for the 10-year risk, that is, intermediate
risk; and 24% is above the high-risk cutoff.
Hence, the strata for comparison of different treat-
ment guidelines are based on prognosis according
to CACS, which approximates the same prognos-
tic meaning as the strata according to EHS or
FRS. This can be further justified according to
the FinRISK study that suggests the total event
rate is 15% at the risk management advice level
of 5% at which it is likely to be intensified [25].Determination of lipid lowering treatment
FRS was calculated based on the original for-
mula set by the Framingham study [28]. The treat-
ment algorithm followed to determine need and
type of treatment of dyslipidemia was as per the
CCS guidelines [4].Statistical analysis
Continuous and categorical variables were
described as means ± standard deviation or counts
and percentages, respectively. Comparisons
between groups were done using independent
t-test for continuous variables, and Chi-square test
or Fisher’s Exact Test, as applicable, for categorical
ones. Agreement between the different risk scor-
ing systems was calculated based on weighted
Kappa coefficients. A value between 0.01 and 0.2
represents slight agreement and a value between
0.21 and 0.4 represents fair agreement [29].
Framingham and European risk scores were calcu-
lated using SigmaPlot 11.0 software (Systat
Software Inc., San Jose, Calif.). Analyses were per-
formed using SPSS version 20.0 (IBM, USA) and
STATA 13.0 software. A p value of 60.05 was used
to indicate significance of tests.CAC acquisition
All CACS examinations were performed on a
64-slice CT scanner (Sensation 64; Siemens
Healthcare, Forchheim, Germany). The scannerhad a gantry rotation time of 300 milliseconds and
a detector row width of 0.6 mm. The scanner
acquired 64 incremental 3-mm slices with prospec-
tive ECG-gating and a flying focus along the z-axis,
covering 2 cm below the carina to the level of
the diaphragm (z-sharp technology; Siemens
Healthcare). The scanner’s temporal resolution
was 75 milliseconds; pitch 3.4; effective mA 80 and
tube voltage 120 kVp. Volume CT dose index and
dose length product (DLP) per scan were recorded
from the scanner console. Effective dose was
obtained by multiplying the DLP of the scan by a
constant factor for the chest per European
Commission guidelines on quality criteria on CT
(k 5 0.014 mSv * mGy21 * cm2). CAC scoring was
performed by the Agatston method [26].Results
Baseline characteristics of the cohort are dis-
played in Table 1. Of the 242 eligible participants,
115 (52.5%) patients had a Coronary Artery
Calcium Score of zero. Gender differences were
significant in terms of age, total and HDL choles-
terol, Agatston Coronary Artery Calcium score,
Framingham risk score, and European Heart
SCORE. Females had significantly higher mean
total cholesterol (209.3 ± 35.0 mg/dL; p = 0.05),
higher mean HDL cholesterol (59.4 ± 18.0 mg/dL;
p < 0.01), and higher mean age (58.9 ± 9.3 years;
p < 0.01). Males had higher CAC score (173.9 ±
476.6AU; p < 0.01), and higher risk of cardiovascu-
lar disease (CVD) as per percent FRS (17.0 ± 12.7%;
p < 0.01), and percent EHS (5.2 ± 9.7%; p < 0.01).
Of the 242 patients, 38.0% were classified as hav-
ing intermediate risk as per FRS, of whom 7.6%
and 77.2% were found to be at high risk and low
risk using CAC score, respectively. Moreover, a
slight agreement level (kappa = 0.143; p < 0.01)
between the two risk assessment tools was calcu-
lated. This low level of agreement was present in
both genders (Tables 2A, B).
On the other hand, as per the EHS, 48.8% of
patients were classified as intermediate risk. Of
this group, 6.8% and 83.1% were found to be at
high risk and low risk using the CAC score
categorization. Again, a slight agreement level
(kappa = 0.087; p < 0.01) between the two risk
assessment tools was calculated (Tables 3A, B).
Analysis of FRS risk score on patients with a
CAC score of zero showed that 10.4% had high
FRS risk while 34.8% had intermediate risk.
The impact of reclassification was demonstrated
in treatment recommendation discrepancies
between the CCS guidelines using the FRS and
CAC score and between the ESC guidelines
FULL LENGTH ARTICLE
Table 1. Baseline characteristics of the study population across gender and age groups.
Variable All (N = 242) Male (N = 169) Female (N = 73) p-value <=50 y.o. (N = 84) 50–65 y.o. (N = 136) >65 y.o. (N = 57) p-value
Continuous variables (Mean ± SD)
Age (years) 56.0 ± 10.0 55.2 ± 10.1 58.9 ± 9.3 <0.01
Body mass index (kg/m2) 31.6 ± 27.5 33.5 ± 33.1 27.6 ± 5.7 >0.05 28.9 ± 4.8 34.1 ± 38.8 29.6 ± 6.0 >0.05
Systolic blood pressure (mmHg) 129.9 ± 18.1 131.0 ± 16.3 127.2 ± 21.5 >0.05 130.3 ± 17.8 128.3 ± 17.1 133.0 ± 20.8 >0.05
Total cholesterol (mg/dl) 197 ± 63.0 192.3 ± 71.0 209.3 ± 35.0 0.05 201.0 ± 46.0 199.0 ± 79.0 188.0 ± 43.0 >0.05
LDL cholesterol (mg/dl) 120.0 ± 36.0 117.9 ± 36.0 124.7 ± 35.0 >0.05 128.0 ± 38.0 117.0 ± 31.0 111.0 ± 38.0 <0.05 p
HDL cholesterol (mg/dl) 50.0 ± 17.0 45.4 ± 14.0 59.4 ± 18.0 <0.01 46.0 ± 19.02 51.0 ± 15.0 53.0 ± 15.0 >0.05
Triglycerides 138.0 ± 107.0 142.8 ± 120.0 128.0 ± 70.0 >0.05 161.6 ± 146.0 127.0 ± 86.0 126.0 ±58.0 >0.05
Calcium score (AU) 137.7 ± 412.9 173.9 ± 476.6 53.7 ± 174.5 <0.01 136.8 ± 51.6 141.5 ± 430.2 359.1 ± 615.1 <0.01 p,¥
Framingham Risk Score (%) 14.8 ± 11.7 17.0 ± 12.7 9.6 ± 6.4 <0.01 10.1 ± 6.6 14.6 ± 10.8 24.0 ± 15.5 <0.01*
European Heart Score (%) 4.4 ± 8.4 5.2 ± 9.7 2.5 ± 3.1 <0.01 1.4 ± 1.3 4.1 ± 9.6 10.5 ± 9.4 <0.01 p,¥
Categorical variables (%)
Age
650 y.o. 34.7 41.4O 19.2O <0.01
50–65 y.o. 46.7 42.0 57.5
>65 y.o. 18.6 16.6 23.3
Hypertension 35.1 37.3 30.1 >0.05 28.6 32.7 53.3 0.01
Antihypertensive medication 28.9 27.8 31.5 >0.05 22.6 27.4 44.4 <0.05
Dyslipidemia 36.4 36.7 35.6 >0.05 29.8 42.5 33.3 >0.05
Smokers 26.9 26.0 28.8 >0.05 31.0 24.8 24.4 >0.05
Family history of CAD 16.7 14.4 22.2 >0.05 19.3 17.0 11.4 >0.05
Non-Zero Calcium score 52.5 60.9 32.9 <0.01 31.0 59.3 75.6 <0.01
 % is within gender.
* all cases significant.
O <=50 y.o. vs 50–65 y.o. significant.
p <=50 y.o. vs >65 y.o. significant.
¥ 50–65 y.o. vs >65 y.o. significant.
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Table 2. Risk categorization for total sample by Coronary Artery Calcium Score and (A) Framingham Risk Score (FRS) and (B)
European Heart SCORE (EHS).
CAC Score Based Risk Categorization Agreement Level
Kappa (p-value)Low (0–99)
N (%)
Intermediate
(100–399) N (%)
High (P400)
N (%)
(A)
FRS Based Risk Categorization Total (N = 242)
Low (<10%) 89 (91.8) 5 (5.2) 3 (3.1) 0.143 (<0.01)
Intermediate (10–20%) 71 (77.2) 14 (15.2) 7 (7.6)
High (>20%) 34 (64.2) 8 (15.1) 11 (20.8)
(B)
EHS Based Risk Categorization Total (N = 242)
Low (<1%) 57 (95.0) 3 (5.0) 0 (0.0) 0.087 (<0.01)
Intermediate (1–5%) 98 (83.1) 12 (10.2) 8 (6.8)
High (>5%) 39 (60.9) 12 (18.8) 13 (20.3)
Table 3. Stratification of treatment indication for total sample as per Coronary Artery Calcium Score (AU) versus (A) Canadian
Cardiology Society (CCS) guidelines and (B) European Society of Cardiology (ESC) guidelines.
Indication to treat as per CCS guidelines using CACS risk
categorization
Agreement Level
Kappa (p-value)
No N (%) Yes N (%)
(A)
CCS guidelines indication to treat Total (N = 242)
No 129 (94.2) 8 (5.8) 0.205 (<0.01)
Yes 79 (75.2) 26 (24.8)
(B)
ESC guidelines indication to treat Total (N = 242)
No 83 (94.3) 5 (5.7) 0.102 (<0.01)
Yes 125 (81.2) 29 (18.8)
J Saudi Heart Assoc
2015;27:234–243
ISMA’EEL ET AL 239
QUANTIFYING THE IMPACT OF USING CORONARY ARTERY
CALCIUM SCORE FOR RISK CATEGORIZATION INSTEAD OF FRAMINGHAM SCORE OR EUROPEAN
HEART SCORE IN LIPID LOWERING ALGORITHMS IN A MIDDLE EASTERN POPULATIONutilizing EHS and CAC score. Of the 242 subjects,
CAC score-based algorithms recommended pre-
ventive lipid lowering treatment for 5.8% of
patients who were not treated as per CCS and for
5.7% who were not treated as per ESC algorithms.
Conversely, 75.2% and 81.2% of those who would
qualify for treatment as per CCS and ESC guideli-
nes, respectively, would not qualify when using
CACS as a tool for risk categorization instead of
the corresponding FRS and EHS systems, respec-
tively. The agreement between CCS FRS based
treatment and CCS CAC score-based treatment
indications was slight (Kappa = 0.205; p < 0.01),
similar to that between ESC EHS based treatment
and ESC CAC score-based algorithms which was
also slight (Kappa = 0.074; p = 0.039). Similar low
levels of agreement were found across gender
and age groups (Supplementary Tables S1–S4).Discussion
Key findings
This study supports several observations. First,
the majority of individuals classified as being at
high risk as per the FRS were down-classified byCACS to intermediate (15.1%) and low risk
(64.2%). Similarly, high risk individuals as per
the EHS were down-classified by CACS to inter-
mediate (15.2%) and low risk (77.2%). Second, of
those at intermediate risk as per the FRS and
EHS, 7.6% and 6.8%, respectively, were up-
classified into high risk category as per CACS.
Third, the downstream implication of using CAC
score based categorization on recommending lipid
lowering treatment was quantified, showing that
this use will lead to recommending treatment to
5.8% and 5.7% of subjects who would have been
left untreated according to CCS and ESC guideli-
nes, respectively. Conversely, of those who would
be treated by CCS and the ESC guidelines, 75.2%
and 81.2%, respectively, would not be treated if
risk categorization was based on CACS. These
two latter observations were in turn reflected in
the fourth finding where the level of agreement
between FRS and CAC score based risk catego-
rization, and between EHS and CAC score based
risk categorization were both slight (kappa
<0.21). Given the increasing adoption of CACS
for risk assessment, and the conflicting down-
stream therapeutic choices noted from these
observations, the implications of these findings
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porting current recommendations in the guideli-
nes is based on randomized clinical trials. This
study is a simulation within a retrospective
design, and thus represents a call for a random-
ized trial to clarify the risks/benefits of such an
approach.Reclassification results in other studies and
how they compare to ours
Results from our study show that a CAC score
P400 AU was recorded in 5.7% of EHS-based
intermediate risk patients and 5.8% of FRS-based
intermediate risk patients; hence up-classifying
them into the high risk category. Furthermore,
77.2% and 83.1% of intermediate risk individuals
as per FRS and EHS, respectively, were found to
have a CAC score <100, placing them in the low
risk category. In fact, 43.5% of subjects with inter-
mediate FRS had a CACS of zero. Accordingly,
these subjects have a 3–5 year event rate of 0.4%
suggesting an event rate of <0.1% [2]. In compar-
ison, Okwuosa et al recorded the distribution of
CACS by Framingham 10-Year Risk Strata in
5660 participants from the MESA cohort using
three cutoff points; CACS >0, P100, and P300,
and they found that 15.6% of individuals with
FRS 10–15% and 24.1% of individuals with FRS
15.1–20% FRS, which comprises the intermediate
risk group, had a CAC P300 AU, and therefore
would be up-classified. They also found that
63.9% and 73.0% of individuals in their two inter-
mediate risk groups had a CAC <100 AU, compris-
ing low CV risk [30]. These observations render
our results of up-classification of approximately
6% in the same range, though slightly lower in
keeping with the higher cut-point used in this
study. On the other hand, the cut-point used for
low risk classification (CACS <100 AU) was the
same in this study and that by Okwuosa et al, ren-
dering the range of down-classification from the
intermediate risk group to also be in the similar
range. Similarly, data from Preis et al showed that
22% of intermediate CHD risk individuals had a
CAC score P90th percentile (high risk as per this
study). This percentage almost doubled to 39%
when using Agatston score with an absolute
CACS cut-point of 100 Hounsfield units [6].
While the utilization of the age–gender percentile
cut-points for risk classification has been used by
some authors, this trend did not appear to be of
significant predictive value compared to absolute
CAC. This has been shown in a study by Budoff
et al, where absolute CAC performed better thanage, sex, and race/ethnicity-specific percentiles
in terms of model fit and discrimination. This
was expressed with a higher area under the recei-
ver–operating characteristic curve for absolute
CAC compared to percentile (women: area under
the curve (AUC) 0.76 versus 0.73, p = 0.044; men:
AUC 0.77 versus 0.73, p < 0.001) [31].Applicability of CVD prevention guidelines
and downstream therapeutic implications
The limitations of the international applicability
of guidelines in general have been highlighted by
the World Health Organization (WHO) [32].
Furthermore, in a recent paper, significant dis-
crepancies in applicability have been noted
between guidelines for CVD prevention and rec-
ommended lipid lowering interventions when
applied on a ‘seemingly healthy’ cohort of persons
in particular [33]. Namely, the ESC 2012 guidelines
[25] and the CCS 2012 guidelines [4] have shown
substantial agreement (Kappa 0.77) for the entire
cohort, but with much lower agreement (Kappa
0.63) when females are considered alone [33].
This underscores the weakness in the applicability
of these guidelines among different ethnicities
and between genders. Moreover, a special con-
cern is underlined in countries where CVD inci-
dence is on the rise, such as Middle Eastern
countries in particular, where it is hypothesized
that currently existing risk scoring systems may
underestimate risk [25]. On the other hand, sev-
eral studies have proven the accuracy of the
CAC score in predicting CVD risk among different
ethnicities and between genders [16,30,34].
Consequently, applying CACS in countries where
no applicability studies for either the FRS or EHS
have been performed will confer greater accuracy
in risk estimation. This is further corroborated by
studies that have demonstrated more refinement
of event prediction by CACS based on the net
reclassification index (NRI).
The accuracy of event prediction using CACS
was demonstrated in the reclassification results
from the Heinz Nixdorf Recall Study which
showed an NRI of 21.7% of FRS-based intermedi-
ate risk subjects to low CAC score (<100) and
30.6% to high CAC P400 [12]. Furthermore, this
result was replicated when Polonsky et al showed
that by adding CACS to their prediction model, a
net reclassification improvement of 25% (95% con-
fidence interval, 16–34%; p < 0.001) from 5,878
healthy, non-diabetic individuals from the MESA
cohort was obtained. Using CAC with the predic-
tion model, approximately 8% were reclassified
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pared to the prediction model by itself, which
accounted for age, sex, tobacco use, systolic blood
pressure, antihypertensive medication use, total
and high-density lipoprotein cholesterol, and
race/ethnicity. In addition, a 23% reclassification
improvement was noted for those who experi-
enced events and 13% for those who did not [35].
Along the same line, data from the Rotterdam
Study also showed that in a cohort of 2,028 asymp-
tomatic participants, 52% of intermediate risk par-
ticipants based on a Framingham refitted risk
model, were reclassified more accurately based
on CAC score, using the cutoff point above
615 AU for high score and below 50 AU for low
score [13]. All these results provide solid evidence
for the cross-gender and cross-ethnic ability of
CACS in risk stratification.
The implications of our results on downstream
lipid-lowering initiation provide a quantitative
assessment to the impact of using CACS for risk
categorization. Our results show that CAC score
based risk categorization recommended preven-
tive lipid lowering treatment for 5.8% of patients
who were not treated as per FRS-based CCS
(Kappa = 0.205; p < 0.01) and for 5.7% who were
not treated as per EHS (Kappa = 0.102; p < 0.01).
Conversely, 75.2% and 81.2% of those who would
qualify for treatment as per the CCS and ESC
guidelines, respectively, would not qualify when
using CACS as a tool for risk categorization. The
low level of agreement noted in the downstream
effects on initiating therapeutics carries serious
concerns and opportunities. First, in countries
where several systems are used, this is space for
confusion in the healthcare system and among
patients. Second, given that efforts to validate
the EHS or FRS systems may be considered in cer-
tain countries, these results highlight the potential
of an algorithm that utilizes CACS which can save
time (waiting for prospective validation) and is
more robust in predicting CV outcomes.
Third, all guidelines for prevention of CVD base
their recommendations to initiate statins on CV
risk categorization using either FRS or EHS,
among other variables. This has led to an increase
in the number of individuals receiving statins. The
risks of statins tend to be accepted by physicians
and patients. However, when results show that
using a different risk scoring system between
70–80% of individuals can be spared this risk, this
is not to be belittled. On the other hand, imple-
menting a CAC scoring based strategy is also
neither risk nor cost-free. Several researchers
have highlighted concerns with radiation fromCAC scoring [36,37]. This would be of more con-
cern if repeated testing were to be recommended
for follow up. While recent technological advances
have led to the reduction of radiation doses [38],
we are uncertain as to how many of the currently
present machines in Lebanon or other parts
of the Middle East use the new radiation limiting
software. Furthermore, the cost of undergoing
repeated CAC scoring is not to be underestimated.
The introduction of cardiac CT angiography in gen-
eral is reported to have increased downstream risk
and cost [39]. The high exclusion rate in our cohort
may suggest that this is also occurring in Lebanon.
Furthermore, unfortunately, no studies from the
Middle East region replicate these cost–benefit
assessments to present a better assessment of
the reality in our area. In this region, it is clearly
the responsibility of governmental agencies to
fund studies that can verify the benefits/
hazards/outcomes of basing recommendations of
lipid lowering on CACS versus FRS or EHS. The
recommendations in the guidelines are based on
double randomized clinical trials that have
demonstrated clinical effectiveness of the cur-
rently widely accepted approach. Despite that,
the proposed approach here can potentially lead
to direct cost savings from not starting statins
and indirect savings from preventing the side
effects of the medications; and the benefits and
risks of such an approach and its effectiveness
compared to the current recommendations need
to be ascertained in a randomized trial before
any recommendations can be made. Of note,
the Society for Heart Attack Prevention and
Eradication (SHAPE) guidelines do incorporate a
CACS based treatment algorithm. However, this
algorithm is limited by a concern that it extra-
polates the proven ability of CACS to classify
risk into the practice of making therapeutic
choices without sufficient evidence to support this,
including clinical effectiveness or cost–benefit
analyses [40].Conclusion
In conclusion, this study has quantitatively sug-
gested that the use of CACS for risk categorization
instead of risk factor based systems such as the
FRS or EHS, would significantly alter treatment
recommendations. Around 6% of those not recom-
mended lipid lowering therapy using risk factor
based systems will be using CACS, and between
70% and 80% of those recommended lipid lower-
ing therapy would be spared this treatment. This
result was similar for both genders. The current
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randomized trials. Our results are a simulation of
a possible alternative path from a retrospective
design and therefore constitute only a call for a
future prospective study to explore the risks/
benefits of such an approach.
This study is limited by its inherent design in
being retrospective within a nested cohort. We
excluded those with >50% stenosis, i.e., obstruc-
tive CAD, since these will normally proceed to
invasive catheterization and will thereafter
require intensive lipid lowering. Our design
addresses the problem of patients with non-
obstructive disease, or <50% stenosis. A potential
source of error in risk prediction in patients with
non-obstructive disease and a CACS rendering
them at low risk is suggested by evidence from
the literature describing non-calcified plaques
and mixed plaques as bearing different outcomes.
This may have occurred in our study and there-
fore limits the conclusions we have reached.
However, data from the CONFIRM registry [15].
l have shown that the ability of CT coronary
angiography to correctly reclassify individuals
from models, including established risk categories
based on the model with Framingham risk factors
plus CACS, was limited. Furthermore, they found
that the NRI from including CT coronary angiog-
raphy data was particularly weak numerically for
all-cause mortality, at 60.05, and was modestly
better for the composite outcome. Thus, we find
it reasonable to use CACS only for CV risk catego-
rization in the <50% stenosis group in particular.
Another limitation in our study is the total num-
ber of individuals included. We admit that using
this sample number to provide generalizations at
a population level is not well-founded and we
therefore recommend a larger study to validate
our findings.Acknowledgements
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